Chen-Chen Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chen-Chen Zhu has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Hao Zhou
1 shared publicationHaojie Zhang
Department of Orthopedics, Xuanwu Hospital of Capital Medical University, Beijing 100053, China
1 shared publicationJiacheng Zhang
Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325027, China
1 shared publication- Jian Xiao
Department of Wound Healing, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
1 shared publication Jianjun Qi
Department of Laboratory Medicine, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu 241001, China
1 shared publicationJiayi Zhao
Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325027, China
1 shared publication
Latest Publications
- Open Access
- 27 October 2026
- Published by Elsevier in Materials Today Bio
- Vol. 41
Ocular delivery of repurposed everolimus against dry eye with a tear-triggered in situ hydrogel based on enhanced solubilization and retention
- 27 October 2026
- Published by Elsevier in Materials Today Bio
- Vol. 41
Open AccessOcular delivery of repurposed everolimus against dry eye with a tear-triggered in situ hydrogel based on enhanced solubilization and retention
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 30
Glial Scar-Targeted Modification of Hepatocyte Growth Factor-Derived Peptide for Spinal Cord Injury Therapeutic Repair
Spinal cord injury (SCI) causes irreversible neural damage and functional impairment. H-RN is a short peptide originating from the kringle 1 domain of hepatocyte growth factor. Despite its efficacy in inhibiting inflammatory responses, the precise neuroprotective mechanisms of the peptide H-RN in SCI remain unclear. The short peptide CAQK can target the lesion epicenter of SCI. To explore the role of the peptide H-RN in SCI and address the numerous challenges faced by conventional drug therapies, this study developed a synthetic peptide, CAQK-H-RN. Our results revealed that CAQK-H-RN could cross the blood–spinal cord barrier, precisely target the SCI region, and increase drug accumulation at the injury site, thereby reducing glial scar formation, decreasing motor neuron death, and enhancing functional recovery after SCI. RNA sequencing was performed to explore the molecular mechanisms of CAQK-H-RN in SCI, which revealed that CAQK-H-RN inhibited pyroptosis and ameliorated lysosomal membrane permeabilization (LMP)-induced autophagic flux disorders in neurons after SCI. Additionally, CAQK-H-RN alleviated LMP by suppressing acid sphingomyelinase activity through the p38 mitogen-activated protein kinase/Ets-like protein-1 (Elk-1)/early growth response protein 1 (Egr-1) signaling cascade and subsequently enhanced autophagy, thereby mitigating neuronal death. This intravenous therapeutic system centered on the synthetic peptide CAQK-H-RN contributes to the functional restoration of SCI, which may be clinically applicable to spinal cord repair.
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 30
Glial Scar-Targeted Modification of Hepatocyte Growth Factor-Derived Peptide for Spinal Cord Injury Therapeutic Repair
Spinal cord injury (SCI) causes irreversible neural damage and functional impairment. H-RN is a short peptide originating from the kringle 1 domain of hepatocyte growth factor. Despite its efficacy in inhibiting inflammatory responses, the precise neuroprotective mechanisms of the peptide H-RN in SCI remain unclear. The short peptide CAQK can target the lesion epicenter of SCI. To explore the role of the peptide H-RN in SCI and address the numerous challenges faced by conventional drug therapies, this study developed a synthetic peptide, CAQK-H-RN. Our results revealed that CAQK-H-RN could cross the blood–spinal cord barrier, precisely target the SCI region, and increase drug accumulation at the injury site, thereby reducing glial scar formation, decreasing motor neuron death, and enhancing functional recovery after SCI. RNA sequencing was performed to explore the molecular mechanisms of CAQK-H-RN in SCI, which revealed that CAQK-H-RN inhibited pyroptosis and ameliorated lysosomal membrane permeabilization (LMP)-induced autophagic flux disorders in neurons after SCI. Additionally, CAQK-H-RN alleviated LMP by suppressing acid sphingomyelinase activity through the p38 mitogen-activated protein kinase/Ets-like protein-1 (Elk-1)/early growth response protein 1 (Egr-1) signaling cascade and subsequently enhanced autophagy, thereby mitigating neuronal death. This intravenous therapeutic system centered on the synthetic peptide CAQK-H-RN contributes to the functional restoration of SCI, which may be clinically applicable to spinal cord repair.